Conditions: HIV Infections Cytomegalovirus Infections
Keywords: HIV CMV T Cell activation Valganciclovir
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 30
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether treatment with valganciclovir decreases T cell activation levels among HIV-infected patients with asymptomatic cytomegalovirus (CMV) co-infection, potentially improving immune responses to antiretroviral therapy.

Detailed description:

Arms:
arm 1: 900mg PO qd arm 2: 900mg PO qd

Interventions: intervention 1: Valganciclovir intervention 2: Placebo
Intervention descriptions: intervention 1: 900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone. intervention 2: Placebo designed to resemble Valganciclovir

Protocol document: